Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000902219-25-000288
Filing Date
2025-08-12
Accepted
2025-08-12 10:34:24
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 9514
2 JOINT FILING AGREEMENT Rule13D_JointFilingAgreement.htm EX-99 3747
  Complete submission text file 0000902219-25-000288.txt   15308
Mailing Address C/O WELLINGTON MANAGEMENT COMPANY LLP 280 CONGRESS STREET BOSTON MA 02210
Business Address C/O WELLINGTON MANAGEMENT COMPANY LLP 280 CONGRESS STREET BOSTON MA 02210 6179515000
WELLINGTON MANAGEMENT GROUP LLP (Filed by) CIK: 0000902219 (see all company filings)

EIN.: 042683227 | State of Incorp.: MA | Fiscal Year End: 1231
Type: SCHEDULE 13G/A
SIC: 0000

Mailing Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 (650) 866-8547
Denali Therapeutics Inc. (Subject) CIK: 0001714899 (see all company filings)

EIN.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-90223 | Film No.: 251204861
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)